Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer)
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Mar 1, 2004 → Aug 1, 2008
NCT ID
NCT00557817About Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer)
Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer) is a phase 2/3 stage product being developed by Amgen for Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00557817. Target conditions include Hematological Malignancies.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00557817 | Phase 2/3 | Completed |
Competing Products
20 competing products in Hematological Malignancies